Harbour Trust & Investment Management Co decreased its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 7.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 39,341 shares of the company's stock after selling 3,238 shares during the period. Harbour Trust & Investment Management Co's holdings in Johnson & Johnson were worth $6,524,000 at the end of the most recent reporting period.
Other institutional investors have also recently made changes to their positions in the company. Lantz Financial LLC grew its position in Johnson & Johnson by 3.3% in the first quarter. Lantz Financial LLC now owns 11,974 shares of the company's stock worth $1,986,000 after acquiring an additional 377 shares in the last quarter. Sulzberger Capital Advisors Inc. purchased a new position in Johnson & Johnson in the fourth quarter worth about $453,000. Horan Securities Inc. grew its position in Johnson & Johnson by 1.3% in the fourth quarter. Horan Securities Inc. now owns 7,178 shares of the company's stock worth $1,038,000 after acquiring an additional 90 shares in the last quarter. State of Wyoming grew its position in Johnson & Johnson by 205,580.0% in the fourth quarter. State of Wyoming now owns 10,284 shares of the company's stock worth $1,487,000 after acquiring an additional 10,279 shares in the last quarter. Finally, Joel Isaacson & Co. LLC boosted its position in shares of Johnson & Johnson by 3.5% during the first quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company's stock valued at $12,294,000 after buying an additional 2,526 shares during the period. Hedge funds and other institutional investors own 69.55% of the company's stock.
Analyst Upgrades and Downgrades
Several brokerages have issued reports on JNJ. Royal Bank Of Canada restated an "outperform" rating and set a $181.00 target price on shares of Johnson & Johnson in a research report on Thursday, June 5th. Sanford C. Bernstein restated a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Morgan Stanley boosted their target price on Johnson & Johnson from $164.00 to $169.00 and gave the company an "equal weight" rating in a research report on Wednesday, April 16th. Wall Street Zen upgraded Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Saturday, June 21st. Finally, The Goldman Sachs Group upgraded Johnson & Johnson from a "neutral" rating to a "buy" rating and boosted their target price for the company from $157.00 to $172.00 in a research report on Wednesday, April 9th. Eleven equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $170.88.
Check Out Our Latest Analysis on Johnson & Johnson
Johnson & Johnson Stock Down 0.5%
NYSE:JNJ traded down $0.78 during trading hours on Monday, reaching $155.23. The company's stock had a trading volume of 6,263,851 shares, compared to its average volume of 8,052,601. The company has a market capitalization of $373.49 billion, a P/E ratio of 17.27, a price-to-earnings-growth ratio of 2.36 and a beta of 0.41. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26. The stock has a 50 day moving average price of $153.67 and a two-hundred day moving average price of $154.24.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. The company had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. Equities analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.
Johnson & Johnson Increases Dividend
The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were given a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, May 27th. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.35%. Johnson & Johnson's dividend payout ratio is presently 57.84%.
Johnson & Johnson Profile
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Read More
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
